๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A rational approach to elucidating the mechanism and location of action of a disease process, or a drug, in vivo

โœ Scribed by Hillman, Harold

Book ID
123105006
Publisher
Elsevier Science
Year
1988
Tongue
English
Weight
774 KB
Volume
12
Category
Article
ISSN
0197-0186

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Mechanism of the uricosuric action of E3
Mechanism of the uricosuric action of E3040, a drug used to treat inflammatory bowel disease II: Study using DBA/2N mice
โœ Harumi Yamada; Hajime Kotaki; Hisao Furitsu; Yasufumi Sawada; Tatsuji Iga ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 186 KB ๐Ÿ‘ 1 views

In the initial phase of clinical studies, it was shown that E3040, a new type of anti-inflammatory drug, reduced plasma uric acid levels. The present study describes a comparison of the excretion of uric acid in the proximal tubules of the kidney after administration of E3040 and its conjugates, sul

Utility of a physiologicallyโ€“based pharm
Utility of a physiologicallyโ€“based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drugโ€“drugโ€“disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice
โœ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- ๐Ÿ“‚ Article ๐Ÿ“… 2012 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4